Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pharmacist Group Says Members Shouldn’t Aid in Executions

By Drug Discovery Trends Editor | April 1, 2015

his May 27, 2008 file photo shows the State of Texas execution chamber in Huntsville, Texas. A leading association for pharmacists on Monday has approved a proposal declaring that participation in lethal injection executions by compounding pharmacies would be a violation of core pharmacy values. (AP Photo/Pat Sullivan)In a move that could heighten the hurdles faced by states attempting to execute prisoners, a leading association for U.S. pharmacists has officially discouraged its members from providing drugs for use in lethal injections.

The policy adopted by American Pharmacists Association delegates at their annual meeting Monday makes an ethical stand against providing such drugs, saying they run contrary to the role of pharmacists as health care providers.

The association lacks legal authority to bar its more than 62,000 members from selling execution drugs, but its policies set pharmacists’ ethical standards.

Pharmacists now join doctors in having national associations with ethics codes that restrict credentialed members from participating in executions.

“Now there is unanimity among all health professions in the United States who represent anybody who might be asked to be involved in this process,” said association member Bill Fassett, who voted in favor of the policy.

Compounding pharmacies, which make drugs specifically for individual clients, only recently became involved in the execution-drug business.

Prison departments turned to made-to-order execution drugs from compounding pharmacies because pharmaceutical manufacturers refused to sell the drugs used for decades in lethal injections after coming under pressure from death penalty opponents.

But now the compounded version is also becoming difficult to come by, with most pharmacists reluctant to expose themselves to possible harassment.

Texas’ prison agency scrambled this month to find a supplier to replenish its inventory before getting drugs from a compounding pharmacy it won’t identify.

Texas Department of Criminal Justice spokesman Jason Clark said Monday that he had no comment when told about the ruling.

After a troubling use of a two-drug method last year, Ohio said it will use compounded versions of either pentobarbital or sodium thiopental in the future, though it doesn’t have supplies of either and hasn’t said how it will obtain them. All executions scheduled this year were pushed to 2016 to give the state more time to find the drugs.

Other states are turning to alternative methods.

Tennessee has approved the use of the electric chair if lethal-injection drugs aren’t available, while Utah has reinstated the firing squad as a backup method if it can’t obtain the drugs. Oklahoma is considering legislation that would make it the first state to allow the use of nitrogen gas as a potential execution method.

Fassett, a professor emeritus of pharmacy law and ethics at Washington State University, said the united front by health professionals might force people to finally face the death penalty’s harsh realities.

Lethal injections have created a sterile setting for executions, he said.

“It’s like we’re not really executing. We’re sort of like taking Spot to the vet. We’re just putting him to sleep, and that’s not true,” he said.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE